Evaluation Addressing Unmet Needs in Ulcerative Colitis: Understanding the Utility of Newer and Emerging Targeted Therapies Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the prevalence, burden, and pathophysiology of UC and associated risk factors for disease development and progression 5 4 3 2 1 Evaluate the mechanisms of action and clinical data associated with newer and emerging drug classes, including S1PR modulators and JAK inhibitors, and their role in the UC treatment paradigm 5 4 3 2 1 Outline strategies for optimizing UC management and addressing treatment challenges in clinical practice 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Millie D. Long, MD, MPH, FACG 5 4 3 2 1 Corey A. Siegel, MD, MS 5 4 3 2 1 Remo Panaccione, MD 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients do you encounter with UC on a weekly basis? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No According to ACG guidelines, mild UC can be defined by which of the following? Continuous blood in stool and continuous urgency, calprotectin >150-200, Mayo endoscopic score 3 Frequent blood in stool and frequent urgency, calprotectin >150-200, Mayo endoscopic score 2 Intermittent presence of blood in stool and occasional urgency, calprotectin >150-200, Mayo endoscopic score 1 No presence of blood in stool and occasional urgency, calprotectin Which of the following best describes the mechanism of action of S1P receptor modulators to address the chronic inflammation associated with the pathogenesis of IBD? Decrease STAT protein phosphorylation Increases anti-inflammatory cytokines to promote gut healing Inhibits cytokine production by epithelial cells and immune cell activation Inhibits recruitment of lymphocytes and reduces the number in systemic circulation Which of the following is a selective S1P receptor modulator (engaging S1P receptors 1, 4, and 5) that demonstrated statistically significant improvements in clinical remission, endoscopic improvement, symptomatic remission, and mucosal healing among patients with moderate to severe UC at weeks 12 and 52? Amiselimod Etrasimod Fingolimod Siponimod How confident are you now in your ability to optimally position S1P receptor modulators and JAK inhibitors in tailored UC treatment plans? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often (select all that apply): Engage in regular, open communication regarding UC management goals with my patients Select UC treatment based on patient characteristics, disease severity, comorbidities, and response to previous therapies Employ shared decision-making strategies to optimize UC outcomes Evaluate the most recent safety and efficacy data associated with current and investigational UC treatments In appropriate patients with UC, consider using newer and emerging therapeutic options that are oral, effective, and have a favorable risk-benefit profile Other, please specify: Previous